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Abstract
Universal access to renal replacement therapy is beyond the economic capability of most
low and middle-income countries due to large patient numbers and the high recurrent cost of
treating end stage kidney disease. In countries where limited access is available, no systems
exist that allow for optimal use of the scarce dialysis facilities. We previously reported that
using national guidelines to select patients for renal replacement therapy resulted in biased
allocation. We reengineered selection guidelines using the ‘Accountability for Reasonable-
ness’ (procedural fairness) framework in collaboration with relevant stakeholders, applying
these in a novel way to categorize and prioritize patients in a unique hierarchical fashion. The
guidelines were primarily premised on patients being transplantable. We examined whether
the revised guidelines enhanced fairness of dialysis resource allocation. This is a descriptive
study of 1101 end stage kidney failure patients presenting to a tertiary renal unit in a middle-
income country, evaluated for dialysis treatment over a seven-year period. The Assessment
Committee used the accountability for reasonableness-based guidelines to allocate patients
to one of three assessment groups. Category 1 patients were guaranteed renal replacement
therapy, Category 3 patients were palliated, and Category 2 were offered treatment if
resources allowed. Only 25.2% of all end stage kidney disease patients assessed were
accepted for renal replacement treatment. The majority of patients (48%) were allocated to
Category 2. Of 134 Category 1 patients, 98% were accepted for treatment while 438 (99.5%)
Category 3 patients were excluded. Compared with those palliated, patients accepted for
dialysis treatment were almost 10 years younger, employed, married with children and not
diabetic. Compared with our previous selection process our current method of priority setting
based on procedural fairness arguably resulted in more equitable allocation of treatment but,
more importantly, it is a model that is morally, legally and ethically more defensible.
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Introduction
End stage kidney disease is a major public health problem globally and its management is asso-
ciated with an economic burden that is particularly onerous on low- and middle-income coun-
tries [1]. Worldwide, the incidence of end stage kidney disease is increasing at approximately
8% annually; global expenditure on maintenance dialysis in the decade spanning the late 1990s
and early 2000s was an estimated US$ 1 trillion [2]. In 2013 the USA alone spent $30.9 billion
treating patients with end stage kidney disease, accounting for 7.1% of the Medicare budget
[3]. This expenditure by the USA solely on the treatment of end stage kidney disease patients
exceeds the total health budget of all but the 29 richest countries in the world and closely
matches the entire South African health budget of US$ 31.8 billion for 2013 [4].
Of the over 2 million people on renal replacement treatment worldwide, 90% are resident in
high-income countries [5]. The correlation between a country’s level of prosperity and the
prevalent dialysis population is now well established [6,7]. In low income countries—home to
over 80% of the world’s population—less than 10% of patients with irreversible kidney failure
have ready access to dialysis [8]. Where patients do have limited access the quality of dialysis is
suboptimal [9]. The situation is gravest in sub-Saharan Africa, the poorest of all the world
regions, where fewer than 1% of end stage kidney disease patients receive renal replacement
treatment [10].
South Africa, a middle-income country, introduced renal replacement therapy in the 1960s,
albeit on a limited basis. Faced with competing health care priorities, access to renal replace-
ment treatment in South Africa is increasingly constrained and the country is grappling with
ways to address the deteriorating situation [11]. In line with practice prevalent in wealthy
countries before universal access to dialysis, an Assessment Committee at our institution for-
mally assessed all patients with end stage kidney failure for enrollment to our renal replace-
ment program. Until 1997 selection of patients was based on informal criteria taking into
account social as well as medical factors that would optimize kidney allograft survival. Since
1997, following a national consensus meeting, the South AfricanNational Department of
Health consolidated the criteria in use to develop a formal national policy on which we subse-
quently based our own criteria.We have reported that, on the basis of such decisions, only 47%
of all patients with end stage kidney disease assessed by our committee over a 15-year period
were accepted for renal replacement treatment. The likelihoodof acceptance into the program
was significantly biased in favor of patients who were employed, married, white and younger
[12]. While we had shown that younger patients had better outcomes, [13], the racial disparity
was a source of great consternation.
Faced with the moral dilemma of improving fairness in access to dialysis, and the need for
an ethical basis for making decisions, our renal team used the accountability for reasonableness
(A4R) approach to develop a hierarchical set of priorities in 2008. In the absence of a definitive
basis in substantive justice for priority making decisions this ethical framework was one that
has been designed to ensure procedurally fair decision-making [14,15].
Material and Methods
The guidelines developed for prioritizing access to our renal replacement therapy program
were based on the best available clinical evidence for good outcomes and the A4R principles of
including relevant stakeholders, transparency, accountability through public access to the
methods used, the availability of an appeals process for review of individual cases and dispute
resolution, and openness to iteratively improve decision-making as new evidence became avail-
able. The team’s experience of local conditions and systems were also considered. The main
premise of the guidelines for acceptance for dialysis remained the ultimate suitability of
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patients for, and optimum outcomes following kidney transplantation, as our resources do not
permit the option of prolonged maintenance dialysis. The relevant stakeholders participating
in drafting the guidelines included non-renal physicians, non-medicalmembers of the renal
team, laypersons, ethicists, lawyers, renal patients, hospital managers and social workers. The
process was an iterative one and culminated in the Department of Health of theWestern Cape
Government formally adopting the policy and implementing it regionally [16].
The guidelines developed included a novel three-tiered hierarchy of priorities, based on the
likelihoodof best outcomes. Patients evaluated by the Committee were allocated to one of
three categories, weighted by medical and social factors. Briefly, Category 1 patients were aged
50 years or less, had no significant comorbid disease and were eminently transplantable. Cate-
gory 3 patients were aged over 60 years, or had severe comorbid disease that either precluded
kidney transplantation or was associated with limited life expectancy. Category 2 patients com-
prised those with clinical and sociological characteristics between these two limits [16]. Impor-
tantly, the renal team concurrently negotiated an agreement with hospital management that all
Category 1 patients would be dialyzed, even if the cap of 100 on the total number of patients on
the dialysis program that serves as entry to the transplant program was exceeded.We also
agreed that Category 2 patients would be dialyzed if resources were available at the time
they required treatment. All Category 3 patients (and Category 2 patients who we could not
accommodate because the program was saturated) would be cared for conservatively with
compassion.
Our teaching hospital based Renal Unit is one of two tertiary referral centers serving adults
with kidney disease inWestern Cape Province; we are responsible for the care of approximately
one-half of theWestern Cape population estimated at 6.1 million (Statistics South Africa,
2014, Pretoria, Statistical Release P0302). The Assessment Committee evaluated a total of 1101
patients with stage 5 chronic kidney disease in the seven year period for enrollment into our
renal replacement treatment program. The mean age of the patients assessed was 41.9 years
(standard deviation ±12.6), and 585 (53.1%) were males. The racial profile generally reflected
that of the population of theWestern Cape: mixed-race 702 (63.8%), black 309 (28.1%), white
75 (6.8%), and foreign nationals 15 (1.4%). The Assessment Committee met once weekly and
comprised the attending physicians, nephrologists, social worker, hospital manager and dialy-
sis staff. Attempts at involving representatives of the community were unsuccessful, as they felt
daunted by the whole process and reluctant to accept the responsibility for making these life or
death decisions. For each patient evaluated medical and social workers’ reports were presented.
The Assessment Committee deliberated the merits of each case based on the guidelines that
had been developed and allocated each patient to one of three categories described.The Cate-
gory 3 and those Category 2 patients not accepted and/or their families were informed of the
committee’s decision soonest possible, with reasons provided for the decision. Patients not
placed were counseled and provided with all necessarymedical care to ensure maximum com-
fort and minimize any suffering; where necessary patients were seen by the social worker and
financial support provided; hospice care was arranged if required. Alternative options were dis-
cussedwith patients and their families, including the possibility of review and of treatment in
the private sector. All decisions were recorded, with reasons.
We reviewed data of all patients evaluated by the Assessment Committee. The data were
collected over the seven-year period included demographic information, social habits, cause of
chronic kidney failure, comorbid diseases, and social information including employment, mar-
ital status and number of dependent children, domicile, the decision of the Assessment Com-
mittee, and documented reasons why patients were refused treatment. The study reviewed data
collected fromMay 1, 2008 to April 30, 2015. Data is presented in one-year intervals from the
commencement date.
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Stata version 13.1 (StataCorp, 2013) statistical software was used to compute summary sta-
tistics and associations between acceptance and other patient covariates. Summary statistics
are reported as means with standard deviation for continuous data, and frequencies with per-
centages for categorical data. Continuous data were analyzed using Student’s t-test and categor-
ical data using the chi-square test. Logistic regression was applied to obtain odds ratios for
acceptance comparing different categories of categorical variables such as employment and
unit change in continuous variables such as age. The confounding effect of patient characteris-
tics was adjusted throughmultivariate logistic regression. For each covariate included in multi-
variate logistic regression, the odds ratio and associated 95% confidence intervals are reported.
Likelihood ratio test was employed to identify the best parsimonious subset of characteristics
with high predictive power. The association between patient characteristics and acceptance was
considered statistically significant if the p-value was less than 5%. To evaluate transplant out-
comes, acturial one-year patient and graft survival rates and their associated 95% confidence
intervals were computed. Graft survival was censored for patient mortality.
Approval to conduct the study was granted by the Human Research Ethics Committee of
StellenboschUniversity (N14/04/028).Waiver of consent was approved by the Committee
because of the challenge of obtaining consent retrospectively. Data were anonymized and de-
identified before analysis and was reported in aggregate.
Results
Over the seven-year period of this study the number of end stage kidney failure patients
assessed by the Assessment Committee fluctuated but with a trend to increase: the total num-
ber of patients ranged from 118 in Year 6 to 189 in Year 7 averaging 157.3 patients annually
(Fig 1). Of the 1101 patients assessed in this period only 277 (25.2%) were accepted for renal
replacement treatment; the acceptance rates fluctuated over the time periodwith a downward
trend (Fig 2). Of all the patients assessed 527 (47.9%) were placed in Category 2 followed by
440 (40.0%) in Category 3 and 134 (12.2%) in Category 1. The relative proportion of patients
in the three assessment categories did not vary significantly over the seven-year period (Fig 1).
Comparative details of patients in the three categories as well as those accepted and treated
conservatively are shown in Table 1. Of the Category 1 patients 132 (98.5%) were accepted for
treatment and 438 (99.5%) Category 3 patients were denied treatment. Of those classified as
Category 2, only 142 (26.9%) could be accommodated on the treatment program. There was a
slight male preponderance (53.0%) of the overall number of patients assessed but significantly
more women were accepted for treatment (149, 28.8%) compared to men (127, 21.7%). Two
patients in Category 1 who were eligible for dialysis treatment elected to receive their treatment
in the private sector, whereas two patients in Category 3 who were refused treatment, requested
that dialysis be initiated after giving guarantees that they would continue treatment in the pri-
vate sector within an agreed period.Diabetes mellitus was significantlymore common as a
cause of end stage kidney failure in the patients refused treatment and less than 4% of patients
with human immunodeficiencyvirus (HIV) infectionwere accepted. Of the hepatitis B virus
infected patients assessed, only 1 (4%) was accepted for treatment. The distance that a patient
resided from a dialysis unit or whether the patient resided in an urban or rural area, did not
influence the decision to accept a patient.
By the end of April 2016, marking one year after the completion of patient entry into the
study, 91 (33.0%) of the patients accepted for treatment had received a primary kidney trans-
plant; of these 48 (17.4%) received their new kidneys within one year. Over the same time
period, 4 (1.4%) received a second transplant and 49 (17.8%) died before they could be trans-
planted. Living donors were the source of 63 (69.2%) of the kidneys transplanted and deceased
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donors for 28. In terms of transplant outcomes, the actuarial one-year patient and graft survival
rates of 92% (95% CI: 84%–96%) and 80% (95% CI: 70%–87%) respectively, with the latter cen-
sored for death.
On multivariate analysis, the odds of receiving treatment was greater for those who were
younger, married, female, had more dependent children, had higher levels of education and
were employed (Table 2). Diabetes reduced the odds of patients being offered treatment by
88%. Only 6.9% of all diabetics assessed were accepted for dialysis. Patients with HIV infection
or hepatitis B infection had 95% and 90% lower odds, respectively, of being treated compared
to those uninfected. Race did not impact on the decision to accept patients for treatment.
The reasons for refusing patients were broadly divided into medical and socioeconomic
(Table 3). The primary reason that a patient was excluded by the committee was documented;
under primary reasons, medical issues were more common than socioeconomicones. Addi-
tional factors contributed in most cases and when the reasons were aggregated socioeconomic
Fig 1. The total number of patients assessed over the period of the study within each assessment category. The majority of patients were
assessed as Category 2, which meant that they could be offered treatment only if facilities were available at the time they required dialysis.
doi:10.1371/journal.pone.0164201.g001
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reasons were more common than medical ones. The fact that a patient was economically
dependent was the most common socioeconomic factor in the primary as well the aggregated
reasons patients were turned down. Under the medical conditions, diabetes mellitus was the
most common reason for refusal and accounted for almost one-quarter of all primarymedical
exclusions, followed by age over 60 years and HIV infection. The remaining listed medical
exclusions accounted for less than 10% each. Under socioeconomic factors, poor adherence to
treatment and drug/alcohol addictionwere the most common psychosocial primary reasons
for exclusion. Socioeconomic factors generally associated with reduced ability to comply or
ability to benefit optimally, included extreme poverty and lack of gainful employment necessi-
tating basic subsistence social grants provided by the state (that allow living at US$2 per day).
Severe obesity (bodymass index greater than 35 kg/m2), cardiovascular disease and hepatitis B
Fig 2. Patient treatment acceptance rates over the seven year time period. The overall acceptance rate was 25.2% (stippled line) with the trend
being downward (dotted line). Acceptance almost halved in the seventh year compared to the first, from 34.8% to 17.5%. The fluctuations in numbers
with increases in Years 4 and 5 were related to slight expansions in the renal replacement program—the capped number of patients we were allowed
to treat was increased from 100 to 120.
doi:10.1371/journal.pone.0164201.g002
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 6 / 16
virus infections were uncommon reasons for exclusions, each accounting for fewer than 5% of
patients refused treatment.
Of the 825 patients selected for conservative treatment, 58 (7%) launched appeals against
the decision. On review the initial decision was upheld in all but three patients (94.5%).
Table 1. Details of the 1101 patients in the three assessment categories compared with each other and the details of patients accepted for renal
replacement treatment compared to those treated conservatively.
Category 1 Category 2 Category 3 P-value Patients for dialysis Patients for palliation OR P-Value
(N = 134) (N = 527) (N = 440) (N = 276) (N = 825)
Mean age, years (±SD) 33.3±10.7 40.7±11.1 46.0±13.2 <0.001 35.8 (±10.9) 44.0 (±12.4) 0.9 <0.001
Male, n (%) 71 (53.0) 267 (50.7) 247 (56.1) 0.236 127 (46.0) 458 (56.0) 0.7 0.006
HIV infected, n (%) 0 (0) 43 (8.2) 60 (13.6) <0.001 4 (1.4) 99 (12.0) 0.1 <0.001
HBV infected, n (%) 0 (0) 9 (1.7) 16 (3.0) 0.023 1 (0.4) 24 (2.9) 0.1 0.039
Smoker n, (%) 24 (17.9) 141 (27.0) 104 (23.6) 0.006 49 (17.8) 220 (26.7) 0.6 0.008
Race, n (%) 0.004
African 25 (18.7) 165 (31.3) 119 (27.1) 64 (23.2) 245 (29.7) REF
Mixed race 98 (73.1) 324 (61.5) 280 (63.6) 189 (68.5) 513 (62.2) 1.4 0.036
White 11 (8.2) 35 (6.6) 29 (6.6) 23 (8.3) 52 (6.3) 1.7 0.067
Foreign nationals 0 (0.0) 3 (0.6) 12 (2.7) 0 (0.0) 15 (1.8) - -
Marital status, n (%) <0.001
Ever married 64 (47.8) 277 (52.6) 198 (45.0) 152 (55.0) 387 (47.0) 1.1 0.445
Never married 67 (50.0) 216 (41.0) 159 (36.1) 115 (42.0) 327 (40.0) REF
Not documented 3 (2.2) 34 (6.5) 83 (18.9) 9 (3.3) 111 (13.5) 0.2 <0.001
Dependents (median (range)) 1 (0–6) 1 (0–8) 0 (0–9) <0.001a 1 (0–7) 0 (0–9) 1.3 <0.001
Not documented 4 65 136 14 191
Domicile, n (%) 0.338
Metropole 114 (85.0) 463 (87.9) 373 (84.7) 243 (88.0) 707 (85.7) REF
Rural 20 (14.9) 64 (12.1) 65 (14.8) 33 (12.0) 116 (14.1) 0.8 0.37
Not documented 0 (0) 0 (0) 2 (0.5) 0 (0) 2 (0.2) -
Education, n (%) <0.001
Illiterate /Primary 16 (11.9) 114 (21.6) 82 (18.6) 31 (11.2) 181 (22.0) REF
Secondary /Tertiary 103 (76.9) 298 (56.5) 175 (39.8) 204 (74.0) 372 (45.1) 3.2 <0.001
Not documented 15 (11.2) 115 (22.0) 183 (41.6) 41 (14.9) 272 (33.0) 0.9 0.619
Employment status <0.001
Employed 119 (88.8) 240 (45.5) 150 (34.1) 214 (78.0.) 298 (36.1) 4.2 <0.001
Pension 0 (0.0) 26 (5.0) 51 (11.6) 1 (0.4) 76 (9.2) 0.1 <0.012
Unemployed 12 (9.0) 223 (42.3) 149 (33.9) 56 (20.3) 328 (40.0) REF
Not documented 3 (2.2) 38 (7.2) 90 (20.4) 6 (2.2) 125 (15.2) 0.3 0.004
Distance n (%) 0.784
Less than 100 km 114 (85.1) 463 (87.9) 373 (84.8) 243 (88.0) 707 (85.7) REF
100–150 km 10 (7.5) 35 (6.6) 37 (8.4) 19 (6.89) 63 (7.6) 0.9 0.631
150–200 km 5 (3.7) 15 (2.8) 14 (3.2) 6 (2.2) 28 (3.4) 0.6 0.300
More than 200 km 5 (3.7) 14 (2.7) 14 (3.2) 8 (2.9) 25 (3.0) 0.9 0.863
Not documented 0 0 2 (0.5) 0 (0.0) 2 (0.2) - -
Primary renal disease, n (%) <0.001
Diabetes mellitus 3 (2.2) 67 (12.7) 90 (20.5) 11 (4.0) 149 (18.1) 0.2 <0.001
Others 131 (97.8) 460 (87.2) 350 (79.6) 266 (96.4) 678 (82.2) REF
a Post hoc analysis: Patients in Category 3 has higher number of dependents compared to 1 and 2; OR, odds ratio; SD, standard deviation; REF, reference
set; HIV, human immunodeficiency virus.; HBV, hepatitis B virus.
doi:10.1371/journal.pone.0164201.t001
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Discussion
Physicians practicing nephrology in low- and middle-income countries face challenges that are
significantly different from those experiencedby their counterparts in well-resourced countries
[1]. The former are faced with a burgeoning population of patients with end stage kidney dis-
ease as a result of aging and the diabetes mellitus epidemic, beside those chronic kidney dis-
eases caused by infectious diseases still prevalent here [17,18]; in high income regions, on the
other hand, the rising incidence of chronic kidney diseases seen in the last four decades of the
last century has stabilized and the last decade has seen a decline in the incidence of the disease
in all age groups [19]. This places undue hardships on economies already strugglingunder the
yoke of the global economic recession further widening heath disparities [20]. Few low- and
middle-income countries have universal access to renal replacement therapy and patients often
have to make out-of-pocket payments for treatment, often leaving families destitute [21].
Where state funding for uninsured patients is restricted it is unclear how patients are selected
for treatment [22,23]. In South Africa, the state supports a limited number of patients on renal
replacement treatment but in the face of other health priorities, the situation for patients with
end stage kidney diseases is deteriorating. In our unit the number of patients with irreversible
kidney disease to whom we were unable to offer treatment increased from 52.7% in 2006 [12]
to almost 75% as reported here. The rising rejection rate is a function of several factors. There
are an increasing number of end stage kidney disease patients requiring renal replacement
treatment. Using available information on theWestern Cape Province’s population of 6.1
Table 2. Multivariate logistic regression analysis of factors impacting on acceptance for renal
replacement treatment.
Variable (N = 892) a Odds Ratio (95% CI) P-value
Age 0.92 (0.90–0.94) <0.001
Gender: male 0.61 (0.43–0.88) 0.007
HIV infected 0.05 (0.02–0.14) <0.001
Diabetic 0.22 (0.10–0.46) <0.001
HBV infected 0.10 (0.01–0.94) 0.044
Marital status
Never married REF
Ever married 3.34 (2.06–5.40) <0.001
Dependents 1.35 (1.16–1.57) <0.001
Educational level
Illiterate/Primary REF
Primary/ Tertiary 3.32 (2.01–5.50) <0.001
Not documented 3.19 (1.63–6.23) 0.001
Employment
Unemployed REF
Employment 4.92 (3.25–7.43) <0.001
Pension 0.18 (0.02–1.41) 0.103
Not documented 1.62 (0.45–5.87) 0.465
Smoking
No REF
Yes 0.55 (0.36–0.86) 0.009
Not documented 2.01 (1.26–3.20) 0.003
a Patients with non-missing data on all the variables included in multivariate analysis; CI, 95% confidence
interval; REF, reference set. HIV, human immunodeficiency virus; HBV, hepatitis B virus.
doi:10.1371/journal.pone.0164201.t002
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million (Statistics South Africa, 2014, Pretoria, Statistical release 1-8-2014), the estimated inci-
dence of end stage kidney disease in South Africa of 250 per million population [24] and our
average transplant and dialysis attrition rates, we have estimated that we currently meet a mere
7.8% of theWestern Cape Province’s dialysis needs, substantially down from the 12.5% at the
start of this project in 2008. The situation is aggravated by a steady decline in the number of
kidney transplants performed in our unit. Reasons for the falling rate of kidney transplants are
likely multifactorial, including changing public awareness and attitudes because of being poorly
informed [25]; a change in the provincial government head injury policy which required head
injury patients with very poor prognosis be managed at the peripheral hospital and not to be
referred to our tertiary institution; the immense burden of trauma means that emergency unit
staff prioritize saving those who are salvageable and passing over opportunities to refer poten-
tial donors because staff and resource constraints [11]; competition for organs with the private
sector with whomwe now share; and bad publicity arising from the sale of organs scandal
[26,27].
The still unraveling global economic crisis has impacted particularly severely on developing
countries like South Africa. These economic realities translate into limited resources being
available for health care, especially relatively costly treatments such as dialysis. South Africa
has a two-tiered health system with 16% of the population insured and guaranteed dialysis
while the remaining 84% relies almost solely on the state for the provision of health services
and hence for access to dialysis and transplantation [28,29]. Our Renal Unit almost exclusively
services the latter, largely indigent population. In terms of resources the total number of
patients we are permitted to treat is capped by the management of the hospital, with the capped
number increasing from 100 to 120 patients over the period of this study. This places an
Table 3. Reasons for patients being refused treatment listed with an aggregate of the individual items.
Primary Secondary Tertiary Plus Aggregatea
(N = 825) (N = 631) (N = 236) (N = 1694) (%)
Medical n = 447 (%) n = 249 (%) n = 73 (%) n = 769
Malignancy 7 (1.6) 8 (3.2) 0 (0.0) 15 (0.9)
Cardiovascular disease 36 (8.1) 21 (8.4) 6 (8.2) 63 (3.7)
Diabetes 110 (24.6) 48 (19.3) 6 (8.2) 164 (9.7)
Age > 60 years 86 (19.2) 57 (22.9) 14 (19.2) 157 (9.3)
HIV infection 74 (16.6) 18 (7.2) 6 (8.2) 98 (5.8)
Other 64 (14.3) 61 (24.5) 31 (42.5) 156 (9.2)
Obese 37 (8.3) 22 (8.8) 3 (4.1) 62 (3.7)
Hepatitis B virus infection 16 (3.6) 5 (2.0) 3 (4.1) 24 (1.4)
Late presentation 17 (3.8) 9 (3.6) 4 (5.5) 30 (1.8)
Sociological n = 378 (%) n = 382 (%) n = 165 (%) n = 925
Unemployed 56 (14.8) 36 (9.4) 22 (13.3) 114 (6.6)
Home circumstances/Distance 8 (2.1) 17 (4.5) 14 (8.5) 39 (2.3)
Poor adherence 60 (15.9) 34 (8.9) 17 (10.3) 111 (6.6)
Lack of dependent children 34 (9.0) 119 (31.2) 59 (35.8) 212 (12.5)
Not breadwinner 115 (30.4) 107 (28.0) 25 (15.2) 247 (14.6)
Drug dependence 58 (15.3) 48 (12.6) 22 (13.3) 128 (7.6)
Foreign nationals 12 (3.2) 2 (0.5) 0 (0.0) 14 (0.8)
Other 35 (9.3) 19 (5.0) 6 (3.6) 60 (3.5)
a In this column the percentages are given for the aggregate
doi:10.1371/journal.pone.0164201.t003
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enormousmoral and ethical burden on the shoulders of the clinical staff responsible for man-
aging these patients. As nephrologists caring for these patients, we have to decide how best to
use ever-dwindling health care resources and severely stretched tertiary healthcare services,
with consideration of both common-good outcomes and individual rights. This balance is
arguably appropriate when spending from a public purse and in the context of limited
resources. As previously argued “. . .the challenge is to create harmony between the rights of
individuals and responsibility to society in ways that promote both individuality and solidarity
and that also sustain the moral integrity of caring health professionals” [30]. There are no sim-
ple solutions to such complex challenges. A test case regarding the ‘right to life’ from renal sup-
port therapy taken to the South African Constitutional Court led to a decision that supported
the principles embraced by the A4R process, thus adding indirect support for this approach
[31].
Against this background a priority-setting process has become critically important with the
challenge being to ensure the most fair, equitable and transparent selection of patients for
access to an increasingly scarce resource [32]. In contrast to other allocative processes that rely
more predominantly on an economic approach, the A4R framework employs an ethical
approach that emphasizes the procedural fairness of rationing decisions. Since it is often diffi-
cult to agree on what decisions are made in the absence of any agreed upon substantive base
for distributive justice, it is more likely consensus can be achieved among relevant stakeholders
on how decisions are made. The A4R framework requires the fulfillment of four procedural
conditions: relevance to the context in which they are made; transparency relating to the rea-
sons for the decisions, accountability through accessibility for public scrutiny, and openness to
challenge or review and leadership/regulatorymechanisms to ensure that these conditions are
met [33,34]. Gibson and her colleagues have argued for a fifth condition, ‘empowerment’, to
allow for more effective participation of various stakeholders [34]. To eliminate all bias Marck-
mann and his colleagues [35], have added consistency, participation and managing conflict of
interests to the list of conditions. There is ongoing refinement of the concept of A4R process
and further research will no doubt be required to test its value and robustness under various
conditions [36].
Our revised guidelines reversed the white racial predominance of patients selectedwe had
previously reported [13], but the predominance of women under the current guidelines is an
unforeseen and unintended outcome. This may be related to mothers playing the main child-
rearing role in single parent households, which are common in the impoverished communities
we serve.Other biases continue to exist: the preponderance of patients reported here who are
married, have children, more highly educated and are employed, and may reflect the persis-
tence of pragmatic, utilitarian considerations among members of the Assessment Committee.
Two main groups of factors militated against patients being enrolled for treatment: associated
medical conditions least favorable to maximizing kidney transplant survival and poor socio-
economic conditions that reduce the ability to comply and the potential for good outcomes.
Compared to our previous report there has been a salutary decline in rejection of patients pri-
marily on socioeconomic criteria but these continued to contribute as factors considered in
decision-making.
In redeveloping the guidelines [16], maintaining the age threshold of 60 years attracted
some controversy. Our patients are considerably younger than patients commenced on dialysis
in high income countries; this relates to the main etiologies of chronic kidney disease being
mainly infective in our population compared to diabetes mellitus in wealthier nations [3,11].
While there is conflicting evidence in the literature of the impact of age on graft and patient
survival [37,38], our decision was supported by data including our own, that increasing age
was associated with poorer graft survival and higher patient mortality [39]. The preference for
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younger patients for dialysis and transplantation has always been a sad reality ever since dialy-
sis became available [40]. Rationing on the basis of age recognizes that the youngest have the
most to lose in terms of life-years and allocation of resources in a ‘youngest first’ approach is in
line that with favoring the worst off, one of eight important principles in allocating scarce
resources [41]. Support for using age as a criterion limiting scarce treatment has been sanc-
tioned by prominent bioethicists including Daniels and Callahan [42,43], with others having
opposing views [44,45]. Obesity, on the increase globally, affects 13.5% of South Africanmen
and 42% of adult women across all ethnic groups [46]. Obesity excluded less than 10% of our
assessed patients from treatment; it is associated with higher acute graft rejection rates and
poorer graft survival although, paradoxically, obese patients survive better on dialysis [47–49].
Being diabetic significantly reduced the odds of acceptance for treatment; in our experience—
shared by others—diabetics fare poorly following kidney transplantation. Compared to non-
diabetics, diabetics are older, fatter, have more underlying cardiovascular disease and after
transplantation more often succumb to cardiovascular disease and infections [50]. Others,
though, have reportedmore favorable experiences [51,52].
HIV infection reduced the odds of acceptance by 95% with only four patients entering our
program. Our reservation in accepting HIV-positive patients relates to limited experience
with kidney transplantation in these patients, although promising results have recently been
reported [53,54]. However, serious challenges remain in managing these patients including the
high risk of acute rejection [55]. Hepatitis B viral infections are associated with adverse renal
transplant outcomes [56,57] and we are unable to afford the nucleoside/nucleotide analogues
that have dramatically improved the outcomes of renal transplantation in infected patients
[58,59]. Active alcohol and recreational drug dependency excluded more than 15% of patients;
alcohol use is an important cause of non-adherence with immunosuppressive regimen [60].
Smoking has been well documented to have a detrimental influence on patient and graft sur-
vival [61–63]. TheWestern Cape population is largely rural and consequently late presentation
and poor adherence are frequent challenges [64]. Studies confirm that the need for urgent dial-
ysis is associated with higher morbidity and mortality and the prolongation of hospital stay
adds to the costs of treating patients presenting late for treatment [65].
A strategy to select patients, such as the one we are proposing, has the potential to maximize
use of scarce resources and minimize the risk of further impoverishing desperate families. At
the same time our approach allows patients who are accepted for treatment to enjoy high qual-
ity medical care. The A4R process we employed was a participative one that led to the develop-
ment of procedurally fair guidelines and a novel approach to categorizing patients. Prior to the
new guidelines, clinicians carried full responsibility for all decisions, even though resource limi-
tation—an economic consideration—was the major factor limiting access to treatment. With
the new approach, clinical managers responsible for the hospital budget participate in the pri-
ority setting process, thus sharing the moral burden of these difficult decisions that are made
within the framework of an institutionally sanctioned priority setting process. To our knowl-
edge this is the first report of the application of the A4R framework to assist in prioritizing
access to dialysis. There are reports of the use of the A4R process in other situations in low-
income countries, the most notable being the Response to Accountable Priority Setting for
Trust in Health Systems (REACT) study launched in 2006 in three central African countries to
improve health outcomes at district level [66,67]. Models of priority setting that rely on techni-
cal approaches such as cost-effectiveness and capacity considerations have often proven unsat-
isfactory and have resulted in a conflict in values such as between equity and efficiency [67]. It
is reassuring to know that the broad approach we have adopted aligns with recent priority set-
tings recommendations made for application at the micro-, meso- and macrolevels of health
care delivery [68,69]. It is also reassuring that the early outcomes delivered in terms of patient
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and graft survival following transplantation are comparable to the outcomes in other low- and
middle income countries [70], justifying our procedural approach to the use of the scarce
resources to optimumbenefit.
As chronic kidney disease becomes an increasingly greater public health challenge, the need
for priority setting seems unavoidable, even among the richest of nations [71,72]. Developing a
clear policy through an evidence based, accountable, transparent and contestable process in
which all stakeholders participate and that takes into consideration relevant values, including
legitimate competing ones, will make it easier to implement and defendmorally, ethically and
legally [14,73].
Conclusion
We have presented a newmodel of hierarchical priority setting, developed using the A4R
framework. The innovation of weighting components in the guidelines has enhanced our deci-
sion-making process. Our model’s greatest success was in ensuring that all patients who were
“ideal” candidates would receive treatment. However, it failed to completely eliminate inequity
related to gender and social circumstances and we will therefore have to continue to review our
guidelines and seek ways to address these challenges.We hope that our experiencewill serve as
an incentive for others, especially those in resource-constrained environments to review their
priority setting practices and take up the challenge of developing their own guidelines using
this values-based approach.
Acknowledgments
We are grateful to all the members of the Assessment Committee who participated diligently in
evaluating all the patients, Ina Steenkamp for meticulous data collection, Theodore Fleischer
for assistance in developing the model and all the clinical and technical staff who participated
in the care of these patients.
Author Contributions
Conceptualization:MRM.
Data curation: JDM.
Formal analysis:MRMMC.
Investigation:MRM JDM.
Methodology:MRM.
Resources:MRM JDM.
Writing – original draft:MRM SB.
Writing – review& editing:MRM SB.
References
1. White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of
renal replacement therapy? Bull World Health Organ. 2008; 86: 229–237. S0042-
96862008000300017 [pii]. doi: 10.2471/BLT.07.041715 PMID: 18368211
2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J
Am Soc Nephrol. 2002; 13 Suppl 1: S37–S40. PMID: 11792760
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 12 / 16
3. United States Renal Data System 2015 USRDS annual data report: Epidemiology of kidney disease in
the United Sates. 2015 National Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2015.
4. The World Bank Total Health Expenditure. 2015. Available: (http://data.worldbank.org/indicator/SH.
XPD.TOTL.ZS). Accessed 16 June 2016.
5. Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing
nations: a 21st century challenge in global health. Nephron Clin Pract. 2011; 118: c269–c277.
000321382 [pii]; doi: 10.1159/000321382 PMID: 21212690
6. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global
dimension and perspectives. Lancet 2013; 382: 260–272. S0140-6736(13)60687-X [pii]; doi: 10.1016/
S0140-6736(13)60687-X PMID: 23727169
7. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient
numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005; 20: 2587–2593.
doi: 10.1093/ndt/gfi159 PMID: 16204281
8. Eggers PW. Has the incidence of end-stage renal disease in the USA and other countries stabilized?
Curr Opin Nephrol Hypertens. 2011; 20: 241–245. doi: 10.1097/MNH.0b013e3283454319 PMID:
21422925
9. Kher V. End-stage renal disease in developing countries. Kidney Int. 2002; 62: 350–362. kid426 [pii];
doi: 10.1046/j.1523-1755.2002.00426.x PMID: 12081600
10. Bamgboye EL. Barriers to a functional renal transplant program in developing countries. Ethn Dis
2009; 19: S1–S9. PMID: 19484877
11. Moosa MR, Meyers AM, Gottlich E, Naicker S. An effective approach to chronic kidney disease in
South Africa. S Afr Med J. 2016; 106: 156–159. doi: 10.7196/SAMJ.2016.v106i2.9928 PMID:
26821893
12. Moosa MR, Kidd M. The dangers of rationing dialysis treatment: the dilemma facing a developing coun-
try. Kidney Int. 2006; 70: 1107–1114. 5001750 [pii]; doi: 10.1038/sj.ki.5001750 PMID: 16883316
13. Moosa MR. Impact of age, gender and race on patient and graft survival following renal transplantation
—developing country experience. S Afr Med J. 2003; 93: 689–695. PMID: 14635558
14. Martin D, Singer P. A strategy to improve priority setting in health care institutions. Health Care Anal.
2003; 11: 59–68. doi: 10.1023/A:1025338013629 PMID: 14510309
15. Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff. (Millwood) 1998;
17: 50–64. doi: 10.1377/hlthaff.17.5.50 PMID: 9769571
16. Moosa MR. Guideline: Priority setting approach in the selection of patients in the public sector with
end-stage kidney failure for renal replacement treatment in the Western Cape Province; 2013. Avail-
able: http://s3.documentcloud.org/documents/19489/moosa-priority-setting-policy-final-feb-24-2010-
final.pdf. Accessed 10 June 2016
17. Barsoum RS. End-stage renal disease in North Africa. Kidney Int Suppl. 2003; S111–S114. kid8322
[pii]; doi: 10.1046/j.1523-1755.63.s83.23.x PMID: 12864887
18. Shaheen FA, Al-Khader AA. Preventive strategies of renal failure in the Arab world. Kidney Int Suppl.
2005; S37–S40. KID9807 [pii]; doi: 10.1111/j.1523-1755.2005.09807.x PMID: 16108969
19. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in preva-
lence of chronic kidney disease in the United States. Trends in prevalence of chronic kidney disease in
the United States. Ann Internl Med. 2016; doi: 10.7326/M16-0273 PMID: 27479614
20. Benatar SR, Gill S, Bakker I. Global health and the global economic crisis. Am J Public Health. 2011;
101: 646–653. AJPH.2009.188458 [pii]; doi: 10.2105/AJPH.2009.188458 PMID: 21330597
21. Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management
issues. Kidney Int Suppl. 2003; S115–S118. kid8323 [pii]; doi: 10.1046/j.1523-1755.63.s83.24.x
PMID: 12864888
22. Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, Gomez-Navarro B, Reyes IH, Lomeli AM,
et al. Renal replacement therapy among disadvantaged populations in Mexico: A report from the
Jalisco Dialysis and Transplant Registry (REDTJAL). Kidney Int. 2005; 68: S58–S61. doi: 10.1111/j.
1523-1755.2005.09710.x PMID: 16014102
23. Sakhuja V, Kohli HS. End-stage renal disease in India and Pakistan: incidence, causes, and manage-
ment. Ethn Dis. 2006; 16: S2–S3. PMID: 16774005
24. Naicker S, Bello AK, El Nahas M. Chronic kidney diseases: Focus on Africa. In: El Nahas M, editor.
Kidney diseases in the developing world and ethnic minorities. London: Taylor and Francis. 2005; pp.
137–160. doi: 10.1201/b14128-8
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 13 / 16
25. Etheredge HR, Turner RE, Kahn D. Public attitudes to organ donation among a sample of urban-dwell-
ing South African adults: a 2012 study. Clin Transplant. 2013; 27: 684–692. doi: 10.1111/ctr.12200
PMID: 23968357
26. Bass D. Kidneys for cash and egg safaris—can we allow ’transplant tourism’ to flourish in South Africa?
S Afr Med J. 2005; 95: 42–44. PMID: 15762247
27. Scheper-Hughes N. Keeping an eye on the global traffic in human organs. Lancet. 2003; 361: 1645–
1648. doi: 10.1016/S0140-6736(03)13305-3 PMID: 12747896
28. Kevany S, Benatar SR, Fleischer T. Improving resource allocation decisions for health and HIV pro-
grammes in South Africa: Bioethical, cost-effectiveness and health diplomacy considerations. Glob
Public Health 2013; 8: 570–587. doi: 10.1080/17441692.2013.790461 PMID: 23651436
29. Mayosi BM, Benatar SR. Health and health care in South Africa—20 years after Mandela. N Engl J
Med. 2014; 371: 1344–1353. doi: 10.1056/NEJMsr1405012 PMID: 25265493
30. Benatar S. Facing ethical challenges in rolling out antiretroviral treatment in resource-poor countries:
comment on "They call it ’patient selection’ in Khayelitsha. Camb Q Health Ethics 2006; 15: 322–330.
doi: 10.1017/S0963180106060427 PMID: 16862936
31. [Anonymous] (1998) Soobramoney v. Minister of Health, Kwa-Zulu Natal. (1998). (1) SA 765 (South
African Constitutional Court).
32. Benatar SR. Health Care Reform and the Crisis of HIV and AIDS in South Africa. N Engl J Med. 2004;
351: 81–92. doi: 10.1056/NEJMhpr033471 PMID: 15229313
33. Daniels N. and Sabin J. Setting Limits Fairly: Can We Learn to Share Medical Resources? Oxford:
2002; Oxford University Press. doi: 10.1093/acprof:oso/9780195149364.001.0001
34. Gibson J, Mitton C, Martin D, Donaldson C, Singer P. Ethics and economics: does programme budget-
ing and marginal analysis contribute to fair priority setting? J Health Serv Res Policy. 2006; 11: 32–37.
doi: 10.1258/135581906775094280 PMID: 16378530
35. Marckmann G, Schmidt H, Sofaer N, Strech D. Putting public health ethics into practice: A systematic
framework. Frontiers in Public Health. 2015; 3:23, e1–e8. doi: 10.3389/fpubh.2015.00023 PMID:
25705615
36. Benatar SR, Ashcroft R. International perspectives on resource allocation. Reference Module in Bio-
medical Sciences. Elsevier. 2015; http://dx.doi.org/10.1016/B978-0-12-801238-3.92830-7
37. Faravardeh A, Eickhoff M, Jackson S, Spong R, Kukla A, Issa N, et al. Predictors of graft failure and
death in elderly kidney transplant recipients. Transplantation. 2013; 96: 1089–1096. doi: 10.1097/TP.
0b013e3182a688e5 PMID: 24056622
38. Fabrizii V, Winkelmayer WC, Klauser R, Kletzmayr J, Sa¨emann MD, Steininger et al. Patient and graft
survival in older kidney transplant recipients: Does age matter? J Am Soc Nephrol. 2004; 15: 1052–
1060. doi: 10.1097/01.ASN.0000120370.35927.40 PMID: 15034109
39. Saudan P, Berney T, Leski M, Morel P, Bolle JF, Martin PY. Renal transplantation in the elderly: a
long-term, single-centre experience. Nephrol Dial Transplant. 2001; 16: 824–828. doi: 10.1093/ndt/
16.4.824 PMID: 11274281
40. Alexander S. They Decide Who Lives, Who Dies: Medical miracle and a moral burden of a small com-
mittee. Life: 1962; 53 September 9: 102–125.
41. Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lan-
cet. 2009; 373: 423–431. doi: 10.1016/S0140-6736(09)60137-9 PMID: 19186274
42. Callahan D. D. Setting limits: medical goals in an aging society. Washington, DC: Georgetown Univer-
sity Press; 1995.
43. Daniels Norman. Am I my parents’ keeper? An essay on justice between the young and the old. Oxford
University Press; 1988.
44. Williams A, Evans JG. The rationing debate: Rationing health care by age. BMJ. 1997; 314: 820. doi:
10.1136/bmj.314.7083.820 PMID: 9081009
45. Rutecki GW. Would treatment allocation according to age-contingent depreciation be ethical? A dialy-
sis and transplantation paradigm. Ethic Med. 2016; 27: 99–107.
46. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national
prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis
for the Global Burden of Disease Study 2013. Lancet. 2014; 384: 766–781. S0140-6736(14)60460-8
[pii]; doi: 10.1016/S0140-6736(14)60460-8 PMID: 24880830
47. Curran SP, Famure Y, Li Z, Kim SJ. Increased recipient body mass index is associated with acute
rejection and other adverse outcomes after kidney transplantation. Transplantation 2014; 97: 64–70.
doi: 10.1097/TP.0b013e3182a688a4 PMID: 24056619
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 14 / 16
48. Aalten J, Christiaans MH, de Fijter H, Hene R, van der Heijde JH, Roodnat J, el at. The influence of
obesity on short- and long-term graft and patient survival after renal transplantation. Transpl Int. 2006;
19: 901–907. TRI367 [pii]; doi: 10.1111/j.1432-2277.2006.00367.x PMID: 17018125
49. Gore JL, Pham PT, Danovitch GM, Wilkinson AH, Rosenthal JT, Lipshutz GS, el at. Obesity and out-
come following renal transplantation. Am J Transplant. 2006; 6: 357–363. AJT1198 [pii]; doi: 10.1111/
j.1600-6143.2005.01198.x PMID: 16426321
50. Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y. Patient survival and cardiovascular risk after
kidney transplantation: the challenge of diabetes. Am J Transplant. 2008; 8: 593–599. AJT2101 [pii];
doi: 10.1111/j.1600-6143.2007.02101.x PMID: 18294155
51. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes
mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001; 15:
89–94. ctr150202 [pii]. doi: 10.1034/j.1399-0012.2001.150202.x PMID: 11264633
52. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal trans-
plantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440–1446. kid582 [pii]; doi:
10.1111/j.1523-1755.2002.kid582.x PMID: 12234317
53. Muller E, Kahn D, Mendelson M. Renal Transplantation between HIV-Positive Donors and Recipients.
N Engl J Med. 2010; 362: 2336–2337. doi: 10.1056/NEJMc0900837 PMID: 20554994
54. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-Infected Liver and Kid-
ney Transplant Recipients: 1- and 3-Year Outcomes. Am J Transplant. 2008; 8: 355–365. doi: 10.
1111/j.1600-6143.2007.02061.x PMID: 18093266
55. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in
HIV-infected recipients. N Engl J Med. 2010; 363: 2004–2014. doi: 10.1056/NEJMoa1001197 PMID:
21083386
56. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, et al. Hepatitis B disease in
dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation. 1987;
44: 369–376. doi: 10.1097/00007890-198709000-00009 PMID: 2820093
57. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation.
Transplantation. 2002; 74: 427–437. doi: 10.1097/00007890-200208270-00001 PMID: 12352899
58. Yap DY, Chan TM. Evolution of hepatitis B management in kidney transplantation. World J Gastroen-
terol. 2014; 20: 468–474. doi: 10.3748/wjg.v20.i2.468 PMID: 24574715
59. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant
recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation. 2010; 90:
325–330. doi: 10.1097/TP.0b013e3181e5b811 PMID: 20562676
60. Denhaerynck K, Steiger J, Bock A, Scha¨fer-Keller P, Ko¨fer S, Thannberger N, el at. Prevalence and
Risk Factors of Non-Adherence with Immunosuppressive Medication in Kidney Transplant Patients.
Am J Transplant. 2007; 7: 108–116. doi: 10.1111/j.1600-6143.2006.01611.x PMID: 17109727
61. Cosio FG, Falkenhain ME, Pesavento TE, Yim S, Alamir A, Henry ML, el at. Patient survival after renal
transplantation: II. The impact of smoking. Clin Transplant. 1999; 13: 336–341. doi: 10.1034/j.1399-
0012.1999.130410.x PMID: 10485376
62. Hurst FP, Altieri M, Patel PP, Jindal TR, Guy SR, Sidawy AN, el at. Effect of Smoking on Kidney Trans-
plant Outcomes: Analysis of the United States Renal Data System. Transplantation 2011; 92: 1101–
1107. doi: 10.1097/TP.0b013e3182336095 PMID: 21956202
63. Moosa MR. Impact of age, gender and race on patient and graft survival following renal transplantation
—developing country experience. S Afr Med J. 2003; 93: 689–695. PMID: 14635558
64. Dogan E, Erkoc R, Sayarlioglu H, Durmus A, Topal C (2005) Effects of late referral to a nephrologist in
patients with chronic renal failure. Nephrology. 2003; 10: 516–519. doi: 10.1111/j.1440-1797.2005.
00433.x PMID: 16221105
65. Smart NA, Titus TT. Outcomes of Early versus Late Nephrology Referral in Chronic Kidney Disease: A
Systematic Review. Am J Med. 2011; 124: 1073–1080. doi: 10.1016/j.amjmed.2011.04.026 PMID:
22017785
66. Maluka S, Kamuzora P, San SM, Byskov J, Olsen OE, Shayo E, el at. Decentralized health care prior-
ity-setting in Tanzania: evaluating against the accountability for reasonableness framework. Soc Sci
Med. 2010; 71: 751–759. S0277-9536(10)00384-9 [pii]; doi: 10.1016/j.socscimed.2010.04.035 PMID:
20554365
67. Byskov J, Bloch P, Blystad A, Hurtig AK, Fylkesnes K, Kamuzora P, el at. Accountable priority setting
for trust in health systems—the need for research into a new approach for strengthening sustainable
health action in developing countries. Health Res Policy Syst. 2009; 7: 23. 1478-4505-7-23 [pii]; doi:
10.1186/1478-4505-7-23 PMID: 19852834
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 15 / 16
68. Norheim OF. Ethical priority setting for universal health coverage: challenges in deciding upon fair dis-
tribution of health services. BMC Med. 2016; 14: 75. doi: 10.1186/s12916-016-0624-4 [pii]. PMID:
27170046
69. Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock D, el at. Guidance on priority setting in
health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis.
Cost Eff Resour Alloc. 2014; 12: 18. doi: 10.1186/1478-7547-12-18 PMID: 25246855
70. Moosa MR. Kidney transplantation in developing countries. In: Morris PJ, Knechtle SJ, editors. Kidney
transplantation: Principles and practice. London: Elsevier Saunders. 2014; pp. 643–675.
71. Vachharajani TJ, Moist LM, Glickman MH, Vazquez MA, Polkinghorne KR, Lok CE, el at. Elderly
patients with CKD—dilemmas in dialysis therapy and vascular access. Nat Rev Nephrol. 2014; 10:
116–122. doi: 10.1038/nrneph.2013.256 PMID: 24296629
72. Carson RC, Juszczak M, Davenport A, Burns A. Is maximum conservative management an equivalent
treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc
Nephrol. 2009; 4: 1611–1619. doi: 10.2215/CJN.00510109 PMID: 19808244
73. Daniels N. Accountability for reasonableness. BMJ. 2000; 321: 1300–1301. doi: 10.1136/bmj.321.
7272.1300 PMID: 11090498
’A4R’ to Improve Fairness in Dialysis Access Allocation
PLOS ONE | DOI:10.1371/journal.pone.0164201 October 4, 2016 16 / 16
